Join Dr. Dara Torgersonon April 29, 2020 at 1:00 pm EST, as she moderates an ATS webinar entitled Genomics of SARS-CoV-2. The presenter, Michael Strong, PhD, is from the National Jewish Health and University of Colorado, in Denver. Dr. Strong will provide an overview of the latest genomics research on SARS-CoV-2, the virus responsible for Coronavirus Disease 2019 (COVID-19) and will address implications for pathogenesis and immunity. Dr. Strong’s research is focused on developing and applying computational methods to better generate, integrate and analyze genomic and proteomic information, with a focus on respiratory disease and disease pathogens. Register hereto attend the webinar.
Irah King: Targeting the gut microbiome to improve COVID-19 disease outcomes
John W. Hanrahan: Targeting coronavirus cation channels with antiviral drugs
Benjamin Smith: PCR-based testing to shorten self-isolation duration in COVID-19 exposed healthcare workers
Dick Menzies, Jonathon Campbell: Assessing costs and benefits of different testing strategies for COVID-19 in Canada
Brett Thombs, Linda Kwakkenbos, Andrea Benedetti, Susan Bartlett, John Varga, Scott Patten, Nicole Culos-Reed, Shannon Hebblethwaite: Mental health in an at-risk population during COVID-19: longitudinal study of risk factors and outcomes and embedded trial of an activity, education, and support intervention
Journalist Alexandre Touchette’s speaks with The Meakins’ Dr. Irah King on Radio Canada April 12, 2020. Dr. King shares several of his hypotheses as to why COVID-19 is found in specific areas of the body. Dr. King is looking to understand what leads to the gastrointestinal symptoms experienced by approximately 20% of those affected with the virus. During the interview, he discuses the gut-lung axis and epithelial and intestinal cells, and speaks to new studies that are trying to decipher why some patients exhibit gastrointestinal symptoms with COVID-19.
Click here to read how Laurent Pharmaceuticals, a McGill spinoff will run a Phase 2 clinical study with LAU-7b, a pro-resolving drug with potential antiviral properties against coronavirus.
Larry Lands is the Chief Medical Advisor for Laurent Pharmaceuticals. Laurent Pharmaceuticals Inc. is planning to test its lead drug LAU-7b in patients with COVID-19 disease. LAU-7b was recently identified as a potential anti-viral therapeutic option for COVID-19 during a drug-library screening effort.
Read more about the “Vermontilator”, and watch the interview with Jason Bates, a lung expert at the UVM Larner College of Medicine.
The Vermontilator would never be used in situations where you have a commercial ventilator. We’re looking at the situation where there are patients dying without available ventilators for them and this would be their lifesaving measure
– Jason Bates
Jason Bates is a Meakins-Christie alumnus. He was a post-doctoral fellow under the supervision of Prof. Joseph Milic-Emili at the Meakins-Christie Laboratories from 1983-1986. Then he was a Meakins-Christie Laboratories research director between 1986-1999.
We would like to take the occasion to remind you that Biosafety Training is mandatory for all laboratory workers. As the training is available online, we encourage those working from home to take advantage of this period, for updating their safety training.
The FRQ will support a new province-wide COVID-19 Biobank. McGill researchers, including Dr. Simon Rousseau, will lead a new task force designed to facilitate and coordinate collection of samples and data from COVID-19 patients across Quebec.
Read the opinion piece co-written by Dr. Faiz Ahmad Khanin the Hill Times – published March 25, 2020 here:
With the arrival of COVID-19, Canada’s health-care system is being tested as never before. Canadian leaders must elicit the assistance of private industry to ensure its continued success, as health-care supplies and equipment are rapidly depleted. A substantial increase in testing for the virus together with significant financial investments in research, aimed at a deeper understanding of the virus and development of a vaccine, should also be top priorities. Solid financial support for all those impacted by the virus will ensure a rapid return to normal once the crisis has abated. Maintaining open communication and collaboration between leaders, the government, and with partners across the board is the key to our ultimate success.